These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 9888705

  • 21. Risk factor analysis of recurrence in low-grade endometrial adenocarcinoma.
    Roma AA, Rybicki LA, Barbuto D, Euscher E, Djordjevic B, Frauenhoffer E, Kim I, Hong SR, Montiel D, Ali-Fehmi R, Malpica A, Silva EG.
    Hum Pathol; 2015 Oct; 46(10):1529-39. PubMed ID: 26264257
    [Abstract] [Full Text] [Related]

  • 22. Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role.
    Espinosa I, José Carnicer M, Catasus L, Canet B, D'angelo E, Zannoni GF, Prat J.
    Am J Surg Pathol; 2010 Nov; 34(11):1708-14. PubMed ID: 20962622
    [Abstract] [Full Text] [Related]

  • 23. IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma.
    Busca A, Djordjevic B, Giassi A, Parra-Herran C.
    Am J Clin Pathol; 2016 Apr; 145(4):486-96. PubMed ID: 27124937
    [Abstract] [Full Text] [Related]

  • 24. The Effect of Adenomyosis in Myometrial Invasion and Overall Survival in Endometrial Cancer.
    Erkilinç S, Taylan E, Gülseren V, Erkilinç G, Karadeniz T, Bağci M, Temel O, Solmaz U, Gökçü M, Sanci M.
    Int J Gynecol Cancer; 2018 Jan; 28(1):145-151. PubMed ID: 29040186
    [Abstract] [Full Text] [Related]

  • 25. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
    Gadducci A, Cosio S, Fanucchi A, Cristofani R, Genazzani AR.
    Anticancer Res; 2000 Jan; 20(3B):1977-84. PubMed ID: 10928137
    [Abstract] [Full Text] [Related]

  • 26. Reassessment of myometrial invasion in endometrial carcinoma.
    Kaku T, Tsuruchi N, Tsukamoto N, Hirakawa T, Kamura T, Nakano H.
    Obstet Gynecol; 1994 Dec; 84(6):979-82. PubMed ID: 7970481
    [Abstract] [Full Text] [Related]

  • 27. CD10 imunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis.
    Srodon M, Klein WM, Kurman RJ.
    Am J Surg Pathol; 2003 Jun; 27(6):786-9. PubMed ID: 12766582
    [Abstract] [Full Text] [Related]

  • 28. [Microcystic, elongated and fragmented invasive pattern in endometrial adenocarcinoma: a clinicopathologic analysis of 72 cases].
    Hu D, Zhang HJ, Shen WC, Zhu WF, Li L, Lin XD, Lu JP, Zheng XW, Wang C, Zhou XR.
    Zhonghua Bing Li Xue Za Zhi; 2017 May 08; 46(5):318-322. PubMed ID: 28468037
    [Abstract] [Full Text] [Related]

  • 29. The association of the microcystic, elongated and fragmented (MELF) invasion pattern in endometrial carcinomas with deep myometrial invasion, lymphovascular space invasion and lymph node metastasis.
    Dogan Altunpulluk M, Kir G, Topal CS, Cetiner H, Gocmen A.
    J Obstet Gynaecol; 2015 May 08; 35(4):397-402. PubMed ID: 25279582
    [Abstract] [Full Text] [Related]

  • 30. Peritumorous lymph-vascular invasion, grade of histologic differentiation, and myometrial infiltration as prognostic factors of endometrial carcinoma.
    De Góis NM, Martins NV, Abrão FS, De Lima GR, Alves AC.
    Rev Paul Med; 1993 May 08; 111(3):385-90. PubMed ID: 8108630
    [Abstract] [Full Text] [Related]

  • 31. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis.
    Nascimento AF, Hirsch MS, Cviko A, Quade BJ, Nucci MR.
    Mod Pathol; 2003 Jan 08; 16(1):22-7. PubMed ID: 12527709
    [Abstract] [Full Text] [Related]

  • 32. Assessment of the depth of myometrial invasion in stage I endometrioid endometrial cancer using pancytokeratin immunohistochemistry.
    Alexander-Sefre F, Singh N, Ayhan A, Thomas JM, Jacobs IJ.
    Int J Gynecol Cancer; 2004 Jan 08; 14(4):665-72. PubMed ID: 15304163
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.
    Gadducci A, Cavazzana A, Cosio S, DI Cristofano C, Tana R, Fanucchi A, Teti G, Cristofani R, Genazzani AR.
    Anticancer Res; 2009 May 08; 29(5):1715-20. PubMed ID: 19443392
    [Abstract] [Full Text] [Related]

  • 38. [MELF pattern in myometrial infiltration in endometrioid adenocarcinoma of the endometrium. A retrospective study of 70 cases].
    Tresserra F, Pascual MÁ, Arenas M, Blancafort C, Martínez-Lanao MÁ, Rodríguez I, Fábregas R.
    Rev Esp Patol; 2018 May 08; 51(2):77-83. PubMed ID: 29602378
    [Abstract] [Full Text] [Related]

  • 39. Accuracy of MRI in predicting deep myometrial invasion in endometrial cancer and the influence of leiomyoma, adenomyosis and the microcystic elongated and fragmented tumour pattern.
    Liyanage A, Cardoza S, Kasabia D, Moore H.
    J Med Imaging Radiat Oncol; 2024 Apr 08; 68(3):235-242. PubMed ID: 38377045
    [Abstract] [Full Text] [Related]

  • 40. Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy.
    Diavolitsis V, Rademaker A, Lurain J, Hoekstra A, Strauss J, Small W.
    Int J Radiat Oncol Biol Phys; 2012 Oct 01; 84(2):415-9. PubMed ID: 22365625
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.